Thomas Jurgensen Net Worth

Thomas Jurgensen biography

Thomas Einar Jurgensen J.D. serves as General Counsel of the Company. Mr. Jurgensen has over 30 years of corporate, transactional and intellectual property legal experience and is licensed to practice in California, Colorado and before the United States Patent and Trademark Office. Mr. Jurgensen is currently in private practice with Optima Law Group. APC in San Diego, California serving as its Managing Shareholder since he founded the firm in February 2011. Optima Law Group serves a diverse base of life science and technology clients with a focus on early stage and emerging companies and also has offices in Boulder, Colorado. He previously served as Managing Shareholder of Catalyst Law Group in San Diego, California from December 2003 to December 2010. From January 2001 to December 2003 he practiced corporate and intellectual property law with the Firm of Blanchard, Krasner and French in La Jolla, California while also serving as the Acting General Counsel of Ligand Pharmaceuticals, Inc. Prior to that, Mr. Jurgensen served as Vice President and General Counsel for The Salk Institute for Biological Studies in La Jolla, California from January 1999 to December 2000, Vice President, General Counsel and Corporate Secretary for Molecular Biosystems, Inc. in San Diego, California from February 1997 to November 1998, and Assistant General Counsel at Ligand Pharmaceuticals, Inc. in San Diego, California from March 1993 to February 1997. Mr. Jurgensen also was an Intellectual Property Attorney at Minnesota Mining and Manufacturing (3M) in St. Paul, Minnesota and an Associate Attorney with the law firm of Merchant and Gould, PA in Minneapolis, Minnesota. Mr. Jurgensen received a Bachelor of Science degree in Biology with a Chemistry minor from the University of Wisconsin River Falls in May 1981. He then received his Master of Science degree in Animal Ecology from Iowa State University in Ames.

What's Thomas Jurgensen's mailing address?

Thomas's mailing address filed with the SEC is 11555 SORRENTO VALLEY ROAD, SUITE 100, , SAN DIEGO, CA, 92121.

Insiders trading at Organovo Inc

Over the last 13 years, insiders at Organovo Inc have traded over $8,085,375 worth of Organovo Inc stock and bought 386,250 units worth $661,443 . The most active insiders traders include Mark Kessel, Keith Murphy et Adam K Stern. On average, Organovo Inc executives and independent directors trade stock every 112 days with the average trade being worth of $29,354. The most recent stock trade was executed by David Gobel on 15 November 2023, trading 19,607 units of ONVO stock currently worth $31,763.

What does Organovo Inc do?

organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.

Organovo Inc executives and stock owners

Organovo Inc executives and other stock owners filed with the SEC include:

• Steven Hughes,
  Chief Medical Officer
• Keith Murphy,
  Executive Chairman and Principal Executive Officer
• Steve Kunszabo,
  VP, Investor Relations & Corporate Communications
• Adam Stern,
  Independent Director
• Alison Milhous,
  Independent Director
• David Gobel,
  Independent Director
• Douglas Cohen,
  Independent Director
• Thomas Jurgensen,
  General Counsel
• Jeffrey Miner,
  Chief Scientific Officer
• Chris Heberlig,
  President, Chief Financial Officer
• David Shapiro,
  Director
• Craig Kussman,
  Chief Financial Officer
• Robert Jr. Baltera,
  Director
• Paul Gallant,
  General Manager
• Jennifer Bush,
  General Counsel & Secretary
• Kirk Malloy,
  Director
• Mark Kessel,
  Director
• Taylor Crouch,
  CEO & President
• James T Glover,
  Director
• Sharon Collins Presnell,
  Chief Scientific Officer
• Richard E Maroun,
  Director
• Tamar D Howson,
  Director
• Kevin Kimberlin,
  10% owner
• Richard A. Heyman,
  Director
• Michael Renard,
  EVP of Commercial Operations
• Andras Forgacs,
  Director
• Barry D Michaels,
  Chief Financial Officer
• Eric David,
  CSO & EVP Pre-Clinical Dev
• Carolyn Beaver,
  Director
• Vaidehi Joshi,